{"id":"NCT01559116","sponsor":"Boehringer Ingelheim","briefTitle":"Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease","officialTitle":"Randomised, Double-blind, Placebo-controlled, 6 Treatment, 4 Period, Incomplete Cross-over Trial to Characterise the 24-hour Lung Function Profiles of Tiotropium + Olodaterol Fixed Dose Combination (2.5/5 µg, 5/5 µg), Tiotropium (2.5 µg, 5 µg) and Olodaterol (5 µg) (Oral Inhalation, Delivered by the Respimat® Inhaler) After 6 Weeks Once Daily Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD) [VIVACITOTM]","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03","primaryCompletion":"2013-08","completion":"2013-08","firstPosted":"2012-03-21","resultsPosted":"2015-07-16","lastUpdate":"2015-07-16"},"enrollment":219,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"tiotropium + olodaterol","otherNames":[]},{"type":"DRUG","name":"tiotropium","otherNames":[]},{"type":"DRUG","name":"olodaterol","otherNames":[]},{"type":"DRUG","name":"tiotropium","otherNames":[]},{"type":"DRUG","name":"tiotropium + olodaterol","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DEVICE","name":"Respimat","otherNames":[]}],"arms":[{"label":"tiotropium+olodaterol FDC low dose","type":"EXPERIMENTAL"},{"label":"tiotropium+olodaterol FDC high dose","type":"EXPERIMENTAL"},{"label":"tiotropium low dose","type":"ACTIVE_COMPARATOR"},{"label":"tiotropium high dose","type":"ACTIVE_COMPARATOR"},{"label":"olodaterol","type":"ACTIVE_COMPARATOR"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of the trial is to determine the 24-hour FEV1-time profile of tiotropium + olodaterol FDC, administered once daily by the RESPIMAT Inhaler after 6 weeks of treatment.","primaryOutcome":{"measure":"Forced Expiratory Volume in 1 Second (FEV1) AUC0-24h Response [L] After 6 Weeks Treatment.","timeFrame":"day 1 and week 6","effectByArm":[{"arm":"Placebo","deltaMin":-0.037,"sd":0.014},{"arm":"Olodaterol (5 µg)","deltaMin":0.129,"sd":0.013},{"arm":"Tiotropium (2.5 µg)","deltaMin":0.117,"sd":0.013},{"arm":"Tiotropium (5 µg)","deltaMin":0.133,"sd":0.014},{"arm":"Tiotropium+Olodaterol FDC (2.5/5 µg)","deltaMin":0.241,"sd":0.014},{"arm":"Tiotropium+Olodaterol FDC (5/5 µg)","deltaMin":0.244,"sd":0.013}],"pValues":[{"comp":"OG000 vs OG005","p":"<0.0001"},{"comp":"OG001 vs OG005","p":"<0.0001"},{"comp":"OG003 vs OG005","p":"<0.0001"},{"comp":"OG000 vs OG004","p":"<0.0001"},{"comp":"OG001 vs OG004","p":"<0.0001"},{"comp":"OG002 vs OG004","p":"<0.0001"},{"comp":"OG003 vs OG004","p":"<0.0001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":29,"countries":["United States","Belgium","Canada","Denmark","Germany","Hungary","Netherlands"]},"refs":{"pmids":["25956072"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":138},"commonTop":["Nasopharyngitis","Chronic obstructive pulmonary disease","Cough","Dyspnoea"]}}